Abstract
INTRODUCTION: Activation of the Hedgehog (HH) pathway is a key factor in the development of basal cell carcinoma. CASE PRESENTATION: Approved HH pathway inhibitors, like vismodegib and sonidegib, are supplied in capsule form. Patients who suffer from dysphagia may have problems swallowing these medications. CONCLUSION: This case report describes the successful use of an alternative administration of sonidegib in a patient with Gorlin-Goltz syndrome and dysphagia.